Michael Hecker

List of Publications by Year
in descending order

64 papers	2,695 citations	186265 28 h-index	189892 50 g-index
66 all docs	66 docs citations	66 times ranked	4802 citing authors

#	Article	IF	Citations
1	Gene regulatory network inference: Data integration in dynamic models—A review. BioSystems, 2009, 96, 86-103.	2.0	663
2	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Science Advances, 2016, 2, e1501678.	10.3	133
3	MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients. International Journal of Molecular Sciences, 2013, 14, 16087-16110.	4.1	112
4	Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept. Arthritis Research and Therapy, 2008, 10, R50.	3.5	108
5	Comprehensive Absolute Quantification of the Cytosolic Proteome of Bacillus subtilis by Data Independent, Parallel Fragmentation in Liquid Chromatography/Mass Spectrometry (LC/MSE). Molecular and Cellular Proteomics, 2014, 13, 1008-1019.	3.8	102
6	MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. Autoimmunity Reviews, 2012, 11, 174-179.	5.8	95
7	Monitoring of multiple sclerosis immunotherapy. Journal of Neurology, 2008, 255, 48-57.	3.6	84
8	Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease—modifying therapies. CNS Neuroscience and Therapeutics, 2019, 25, 245-254.	3.9	68
9	Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms. Scientific Reports, 2016, 6, 34512.	3.3	63
10	Fluorescent-increase kinetics of different fluorescent reporters used for qPCR depend on monitoring chemistry, targeted sequence, type of DNA input and PCR efficiency. Mikrochimica Acta, 2014, 181, 1689-1696.	5.0	62
11	Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. Autoimmunity Reviews, 2015, 14, 903-913.	5.8	61
12	High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. Molecular and Cellular Proteomics, 2016, 15, 1360-1380.	3.8	60
13	Integration of MicroRNA Databases to Study MicroRNAs Associated with Multiple Sclerosis. Molecular Neurobiology, 2012, 45, 520-535.	4.0	58
14	Dysregulation of Inflammasome Priming and Activation by MicroRNAs in Human Immune-Mediated Diseases. Journal of Immunology, 2019, 202, 2177-2187.	0.8	53
15	Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. Journal of Neuroinflammation, 2012, 9, 140.	7.2	50
16	Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells. PLoS ONE, 2013, 8, e70626.	2.5	43
17	Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-β-1b treatment in relapsing remitting MS. Pharmacogenomics, 2010, 11, 147-161.	1.3	42
18	Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing—remitting multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1202-1214.	3.0	40

#	Article	IF	Citations
19	Computational analysis of high-density peptide microarray data with application from systemic sclerosis to multiple sclerosis. Autoimmunity Reviews, 2012, 11, 180-190.	5.8	39
20	Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis. Scientific Reports, 2017, 7, 42087.	3.3	37
21	Interferon Î²-1a and Î²-1b for patients with multiple sclerosis: updates to current knowledge. Expert Review of Clinical Immunology, 2018, 14, 137-153.	3.0	36
22	Frequencies of Polymorphisms in Cytokines, Neurotransmitters and Adrenergic Receptors in Patients With Complex Regional Pain Syndrome Type I After Distal Radial Fracture. Clinical Journal of Pain, 2010, 26, 175-181.	1.9	35
23	Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patientsâ€™ individual gene expression in peripheral blood. Molecular Neurobiology, 2013, 48, 737-756.	4.0	35
24	Integrative modeling of transcriptional regulation in response to antirheumatic therapy. BMC Bioinformatics, 2009, 10, 262.	2.6	33
25	Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2011, 6, e29648.	2.5	33
26	Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosineâ€‑1â€‘phosphate receptor modulator. CNS Neuroscience and Therapeutics, 2018, 24, 193-201.	3.9	32
27	Polypharmacy among patients with multiple sclerosis: a qualitative systematic review. Expert Opinion on Drug Safety, 2020, 19, 139-145.	2.4	32
28	Towards a proteome signature for invasive ductal breast carcinoma derived from label-free nanoscale LC-MS protein expression profiling of tumorous and glandular tissue. Analytical and Bioanalytical Chemistry, 2009, 395, 2443-2456.	3.7	31
29	Network analysis of transcriptional regulation in response to intramuscular interferon-Î²-1a multiple sclerosis treatment. Pharmacogenomics Journal, 2012, 12, 134-146.	2.0	31
30	Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy. Pharmacogenomics, 2011, 12, 423-432.	1.3	25
31	Mass Spectrometric Characterization of Protein Structure Details Refines the Proteome Signature for Invasive Ductal Breast Carcinoma. Journal of the American Society for Mass Spectrometry, 2011, 22, 440-456.	2.8	25
32	Leukocyte Telomere Length in Patients with Multiple Sclerosis and Its Association with Clinical Phenotypes. Molecular Neurobiology, 2021, 58, 2886-2896.	4.0	22
33	Epitope Predictions Indicate the Presence of Two Distinct Types of Epitope-Antibody-Reactivities Determined by Epitope Profiling of Intravenous Immunoglobulins. PLoS ONE, 2013, 8, e78605.	2.5	20
34	Aberrant expression of alternative splicing variants in multiple sclerosis â€“ A systematic review. Autoimmunity Reviews, 2019, 18, 721-732.	5.8	19
35	Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors. Scientific Reports, 2019, 9, 3743.	3.3	19
36	Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis. Biomolecules, 2021, 11, 1510.	4.0	19

#	Article	IF	Citations
37	Polypharmacy in patients with multiple sclerosis: a gender-specific analysis. Biology of Sex Differences, 2019, 10, 27.	4.1	18
38	Systematic Review of Studies on Telomere Length in Patients with Multiple Sclerosis. , 2021, 12, 1272.		18
39	Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: A single-center study. PLoS ONE, 2019, 14, e0211120.	2.5	17
40	A genetic variant associated with multiple sclerosis inversely affects the expression of CD58 and microRNA-548ac from the same gene. PLoS Genetics, 2019, 15, e1007961.	3.5	17
41	High-Resolution Expression Profiling of Peripheral Blood CD8+ Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution. Molecular Neurobiology, 2017, 54, 5511-5525.	4.0	16
42	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. Genetic Epidemiology, 2015, 39, 601-608.	1.3	15
43	Susceptibility variants in the CD58 gene locus point to a role of microRNA-548ac in the pathogenesis of multiple sclerosis. Mutation Research - Reviews in Mutation Research, 2015, 763, 161-167.	5.5	15
44	Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary. Advances in Therapy, 2016, 33, 834-847.	2.9	15
45	Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients. Journal of Neuroinflammation, 2013, 10, 126.	7.2	14
46	Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater‑blinded analysis of relapse rates during pregnancy and the postnatal period. CNS Neuroscience and Therapeutics, 2019, 25, 78-85.	3.9	12
47	Association of smoking but not HLA-DRB1*15:01, *APOE* or body mass index with brain atrophy in early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 661-668.	3.0	12
48	Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy. Scientific Data, 2018, 5, 180145.	5.3	12
49	Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis. Acta Neurologica Scandinavica, 2017, 136, 116-121.	2.1	11
50	Polypharmacy in Chronic Neurological Diseases: Multiple Sclerosis, Dementia and Parkinson's Disease. Current Pharmaceutical Design, 2021, 27, 4008-4016.	1.9	11
51	Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642097564.	3.5	9
52	An Inventory of Short Term and Long Term Changes in Gene Expression Under Interferon β Treatment of Relapsing Remitting MS Patients. Current Pharmaceutical Design, 2012, 18, 4475-4484.	1.9	9
53	The risk of polypharmacy, comorbidities and drug‑drug interactions in women of childbearing age with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642096950.	3.5	9
54	Principles and Practical Considerations for the Analysis of Disease-Associated Alternative Splicing Events Using the Gateway Cloning-Based Minigene Vectors pDESTsplice and pSpliceExpress. International Journal of Molecular Sciences, 2021, 22, 5154.	4.1	8

#	Article	IF	Citations
55	Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy. Pharmaceutics, 2022, 14, 592.	4.5	8
56	Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy. BMC Neurology, 2016, 16, 181.	1.8	7
57	Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis. EBioMedicine, 2022, 80, 104052.	6.1	7
58	Blood transcriptome profiling captures dysregulated pathways and response to treatment in neuroimmunological disease. EBioMedicine, 2019, 49, 2-3.	6.1	4
59	General Principles of Immunotherapy in Neurological Diseases. Contemporary Clinical Neuroscience, 2019, , 387-421.	0.3	3
60	Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis. Journal of Personalized Medicine, 2022, 12, 677.	2.5	3
61	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. Cells, 2020, 9, 175.	4.1	1
62	Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110243.	2.5	1
63	Molekularbiologische Untersuchungen bei multipler Sklerose. , 2015, , 211-214.		0
64	Molekularbiologische Untersuchungen bei MS. , 2018, , 207-210.		0